PL3539543T3 - Pirydylohydrazyny w leczeniu gruźlicy i chorób pokrewnych - Google Patents
Pirydylohydrazyny w leczeniu gruźlicy i chorób pokrewnychInfo
- Publication number
- PL3539543T3 PL3539543T3 PL19167996T PL19167996T PL3539543T3 PL 3539543 T3 PL3539543 T3 PL 3539543T3 PL 19167996 T PL19167996 T PL 19167996T PL 19167996 T PL19167996 T PL 19167996T PL 3539543 T3 PL3539543 T3 PL 3539543T3
- Authority
- PL
- Poland
- Prior art keywords
- hydrazones
- tuberculosis
- pyridyl
- treatment
- related diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C07D213/77—Hydrazine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT106652A PT106652A (pt) | 2012-11-20 | 2012-11-20 | Piridil hidrazonas para o tratamento de tuberculose e doenças relacionadas |
PT2012106652 | 2012-11-20 | ||
EP13811632.2A EP2922541B1 (en) | 2012-11-20 | 2013-11-20 | Pyridyl hydrazones for the treatment of tuberculosis and related diseases |
PCT/PT2013/000068 WO2014081324A1 (en) | 2012-11-20 | 2013-11-20 | Pyridyl hydrazones for the treatment of tuberculosis and related diseases |
EP19167996.8A EP3539543B1 (en) | 2012-11-20 | 2013-11-20 | Pyridyl hydrazones for the treatment of tuberculosis and related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3539543T3 true PL3539543T3 (pl) | 2022-01-10 |
Family
ID=49876952
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL19167996T PL3539543T3 (pl) | 2012-11-20 | 2013-11-20 | Pirydylohydrazyny w leczeniu gruźlicy i chorób pokrewnych |
PL13811632T PL2922541T3 (pl) | 2012-11-20 | 2013-11-20 | Hydrazony pirydylowe do leczenia gruźlicy i chorób pokrewnych |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13811632T PL2922541T3 (pl) | 2012-11-20 | 2013-11-20 | Hydrazony pirydylowe do leczenia gruźlicy i chorób pokrewnych |
Country Status (15)
Country | Link |
---|---|
US (1) | US9593103B2 (pl) |
EP (2) | EP2922541B1 (pl) |
BR (1) | BR112015011606A2 (pl) |
CY (2) | CY1121861T1 (pl) |
DK (1) | DK2922541T3 (pl) |
ES (2) | ES2899437T3 (pl) |
HR (2) | HRP20211767T1 (pl) |
HU (2) | HUE056531T2 (pl) |
LT (2) | LT3539543T (pl) |
MA (1) | MA38206B1 (pl) |
PL (2) | PL3539543T3 (pl) |
PT (3) | PT106652A (pl) |
RS (2) | RS62579B1 (pl) |
SI (2) | SI3539543T1 (pl) |
WO (1) | WO2014081324A1 (pl) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3716131A1 (de) * | 1987-05-14 | 1988-12-01 | Forsch Borstel Inst Fuer Exper | Substituierte 2-acylpyridin-(alpha)-(n)-hetarylhydrazone sowie diese enthaltende arzneimittel |
US8865901B2 (en) * | 2009-10-02 | 2014-10-21 | Fred Hutchinson Cancer Research Center | Gain-of-function Bcl-2 inhibitors |
EP2311457A1 (en) * | 2009-10-19 | 2011-04-20 | Forschungszentrum Borstel | Pharmaceutical compositions for treating infections with drug resistant mycobacteria |
-
2012
- 2012-11-20 PT PT106652A patent/PT106652A/pt unknown
-
2013
- 2013-11-20 PL PL19167996T patent/PL3539543T3/pl unknown
- 2013-11-20 LT LTEP19167996.8T patent/LT3539543T/lt unknown
- 2013-11-20 HU HUE19167996A patent/HUE056531T2/hu unknown
- 2013-11-20 LT LTEP13811632.2T patent/LT2922541T/lt unknown
- 2013-11-20 ES ES19167996T patent/ES2899437T3/es active Active
- 2013-11-20 HR HRP20211767TT patent/HRP20211767T1/hr unknown
- 2013-11-20 PT PT191679968T patent/PT3539543T/pt unknown
- 2013-11-20 RS RS20211433A patent/RS62579B1/sr unknown
- 2013-11-20 DK DK13811632.2T patent/DK2922541T3/da active
- 2013-11-20 ES ES13811632T patent/ES2741434T3/es active Active
- 2013-11-20 EP EP13811632.2A patent/EP2922541B1/en active Active
- 2013-11-20 SI SI201331949T patent/SI3539543T1/sl unknown
- 2013-11-20 SI SI201331543T patent/SI2922541T1/sl unknown
- 2013-11-20 US US14/646,197 patent/US9593103B2/en active Active
- 2013-11-20 EP EP19167996.8A patent/EP3539543B1/en active Active
- 2013-11-20 RS RSP20191006 patent/RS59224B1/sr unknown
- 2013-11-20 PT PT13811632T patent/PT2922541T/pt unknown
- 2013-11-20 PL PL13811632T patent/PL2922541T3/pl unknown
- 2013-11-20 WO PCT/PT2013/000068 patent/WO2014081324A1/en active Application Filing
- 2013-11-20 BR BR112015011606A patent/BR112015011606A2/pt not_active Application Discontinuation
- 2013-11-20 MA MA38206A patent/MA38206B1/fr unknown
- 2013-11-20 HU HUE13811632A patent/HUE045502T2/hu unknown
-
2019
- 2019-08-02 HR HRP20191402 patent/HRP20191402T1/hr unknown
- 2019-08-06 CY CY20191100833T patent/CY1121861T1/el unknown
-
2021
- 2021-11-26 CY CY20211101030T patent/CY1124836T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI2922541T1 (sl) | 2019-10-30 |
PL2922541T3 (pl) | 2019-10-31 |
US9593103B2 (en) | 2017-03-14 |
ES2741434T3 (es) | 2020-02-11 |
LT2922541T (lt) | 2019-09-25 |
MA38206B1 (fr) | 2019-03-29 |
EP3539543B1 (en) | 2021-09-01 |
PT106652A (pt) | 2014-05-20 |
SI3539543T1 (sl) | 2022-01-31 |
DK2922541T3 (da) | 2019-08-12 |
CY1121861T1 (el) | 2020-07-31 |
RS59224B1 (sr) | 2019-10-31 |
MA38206A1 (fr) | 2017-12-29 |
EP2922541B1 (en) | 2019-05-22 |
US20150284374A1 (en) | 2015-10-08 |
CY1124836T1 (el) | 2022-11-25 |
LT3539543T (lt) | 2021-12-27 |
ES2899437T3 (es) | 2022-03-11 |
RS62579B1 (sr) | 2021-12-31 |
HRP20191402T1 (hr) | 2019-11-15 |
PT3539543T (pt) | 2021-11-22 |
HRP20211767T1 (hr) | 2022-02-18 |
WO2014081324A1 (en) | 2014-05-30 |
PT2922541T (pt) | 2019-08-26 |
BR112015011606A2 (pt) | 2017-07-11 |
EP2922541A1 (en) | 2015-09-30 |
HUE045502T2 (hu) | 2019-12-30 |
HUE056531T2 (hu) | 2022-02-28 |
EP3539543A1 (en) | 2019-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1217033A1 (zh) | 遺傳變異的無創評估方法和流程 | |
HK1214870A1 (zh) | 非侵入性遺傳變異評估的方法及流程 | |
HK1205938A1 (en) | Inhibitors of human ezh2, and methods of use thereof ezh2 | |
EP2890440A4 (en) | DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES | |
EP3004083A4 (en) | COMPOUNDS FOR THE TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | |
IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
HUE041553T2 (hu) | Lizoszomális tárolási betegségek (LSD) kezelése és génterápia | |
HK1206937A1 (en) | Methods of administering pirfenidone therapy | |
HRP20180345T1 (hr) | Derivati sterola i njihova upotreba u liječenju bolesti koje uključuju transformirane astrocitne stanice, ili u liječenju zloćudnih hemopatija | |
HK1218882A1 (zh) | 用於治療神經退化疾病和其它疾病的組合治療劑和方法 | |
EP2710017A4 (en) | MACROCYCLIC THERAPEUTIC AGENTS AND METHODS OF TREATMENT | |
ZA201503266B (en) | Pyidone derivatives and uses thereof in the treatment of tuberculosis | |
EP2817004A4 (en) | BOUVARDIN DERIVATIVES AND THEIR THERAPEUTIC USES | |
HRP20182198T1 (hr) | Kinolil hidrazona za liječenje tuberkuloze i srodnih bolesti | |
SI3539543T1 (sl) | Piridil hidrazoni za zdravljenje tuberkuloze in sorodnih bolezni | |
AP2015008270A0 (en) | Preparation for the treatment of tuberculosis | |
AU2012902982A0 (en) | Compositions and methods for the treatment of tuberculosis |